CF Acquisition Corp. VII (NASDAQ: CFFS) announced this afternoon that it is postponing its extension meeting, originally scheduled for June 14, until 10 a.m. ET on June 16.
In connection with the postponed meeting, CFFS has also extended the redemption deadline to 5 p.m. ET on June 14.
The SPAC is currently facing a completion deadline of June 20, but is seeking shareholder approval to extend its timeline by nine months until March 20, 2024. If the extension is approved and implemented, the sponsor will deposit into the trust $0.03 per month for each public share that is not redeemed for each month that is needed to complete a business combination until the deadline.
Although CF VII has not found a target to combine with just yet, it intends to focus its search on the financial services, healthcare, real estate services, technology and software industries. The company is led by Chairman and CEO Howard W. Lutnick, President Anshu Jain, and CFO Jane Novak.
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Heard on the Street: VinFast’s SPAC Backers Are Backing Out Even by the standards of electric-vehicle startups, the $40 billion market value of Vietnamese electric-vehicle startup VinFast is wild, following its combination with Black Spade last month....
Murphy Canyon (NASDAQ:MURF) announced this morning that it has closed its combination with Conduit Pharmaceuticals and its shares and warrants are expected to begin trading on the Nasdaq under the symbols “CDT” and “CDTTW” on September 25. The company also closed a purchase of $20 million in Murphy Canyon units at close, which is to...
Indie Semiconductor (NASDAQ:INDI), which merged with Thunder Bridge II in June 2021, announced this morning that it has launched an exchange offer to convert each outstanding warrant to 0.285 Class A shares in the company. At Indie’s last closing price of $6.22, this is $1.77 of value each, although the stock has been rising since...
Atlantic Coastal II (NASDAQ:ACAB) has entered into a definitive agreement to combine with drug developer Abpro at a valuation of $725 million. Woburn, Massachusetts-based Abpro is advancing a series of drug candidates to potentially treat COVID, cancer and diabetic blindness. The combined company is expected to trade on the Nasdaq once the deal is completed...
Graf Acquisition Corp. IV (NYSE:GFOR) announced that it adjourned Wednesday’s completion vote for its combination with NKGen Biotech without conducting any business and will reopen proceedings at 4:00 p.m., Eastern time, on September 25, 2023 Once again, the adjournment is being done to provide additional time to continue its efforts to obtain additional financing. This new...